Based on various studies, scientific evidence has proven the effectiveness of whole-body electromyostimulation (WB-EMS) on parameters such as increased physiological performance and body composition. As a pilot project, the aim of the study is to determine the effect of additional WB-EMS as part of the inpatient four-week rehabilitation of sarcopenic subjects.
The loss of muscle mass in the age-associated process (sarcopenia) is a common indication in the field of orthopedic and cardiac rehabilitation, which may also be reinforced by previous immobilization and disuse of the muscles (atrophy of muscle). Sarcopenia is defined as 2 standard deviations of average of the same sex in middle adult life. The present project focuses on the sarcopenia definition of the Foundation for the National Institutes of Health (FNIH). Their limits are \< 0.789 (men) and \< 0.512 (women) and are calculated by adding the absolute muscle mass of the extremities divided by the body mass index (BMI). Due to reduced muscle mass and thus limited strength / performance, the implementation of conventional training tools with regard to generate corresponding intensities is no longer possible, or in persons with additional cardiac or orthopedic restrictions heavily limited. In view of the existing indications, the alternative training technology whole-body electromyostimulation (WB-EMS) is an adequate training tool for the rehabilitation process. The time-saving (max 20 minutes per training session) and effective training method is characterized by low orthopedic and cardiac stress. Thus, WB-EMS combines both relevant aspects of a joint-friendly training with effects on muscle mass and functionality. Through the simultaneous activation of up to 10 muscle regions with corresponding, subjectively decidedly adjustable intensity per muscle group, up to 2,800 cm2 can be addressed. Synchronized to a motion video, the participants perform light physical exercises in parallel to the current pulses. The aim of the study is, to evaluate the effect of additional WB-EMS during a 4-week period of inpatient rehabilitation, comparing 3 groups: 1. WB-EMS, stimulating 8 muscle groups (legs,arms, core, gluteal region) 2. partial-WB-EMS, just stimulating the lower extremities (legs, gluteal region) 3. control, just performing the functional, mainly eccentric motion pattern without stimulation
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
134
whole body electromyostimulation
20 min of pronounced eccentric movement patterns
Klinik Königsfeld der DRV
Ennepetal, North Rhine-Westphalia, Germany
(isometric) muscle strength of arms, legs and trunk (extenstion)
isometric strength \[Nm\] (DIERs Myoline professional, DIERs International GmbH)
Time frame: 4 weeks
muscle function
chair rise test \[repetitions; n\]
Time frame: 4 weeks
muscle function / submaximal performance test
6 minute walking test \[distance; m\]
Time frame: 4 weeks
muscle mass via multifrequency bioimpedance analysis
via multifrequency bioimpedance analysis (BIA, Inbody770, Seoul, Korea)
Time frame: 4 weeks
body fat via multifrequency bioimpedance analysis
via multifrequency bioimpedance analysis (BIA, Inbody770, Seoul, Korea)
Time frame: 4 weeks
blood-sample: triglycerides
blood-sample
Time frame: 4 weeks
blood-sample: high-density lipoprotein (HDL)
blood-sample
Time frame: 4 weeks
blood-sample: low-density lipoprotein (LDL)
blood-sample
Time frame: 4 weeks
blood-sample: Crea/glomerular filtration rate (GfR)
blood-sample
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 4 weeks
blood-sample: glutamate oxaloacetate transaminase (GOT)
blood-sample
Time frame: 4 weeks
blood-sample: glutamic pyruvic transaminase (GPT)
blood-sample
Time frame: 4 weeks
blood-sample: gamma-glutamyl transpeptidase (GGT)
blood-sample
Time frame: 4 weeks
blood-sample: creatine kinase (CK)
blood-sample
Time frame: 4 weeks
blood-sample: myoglobin
blood-sample
Time frame: 4 weeks
blood-sample: sodium
blood-sample
Time frame: 4 weeks
potassium
blood-sample
Time frame: 4 weeks
life quality
questionnaire: Short Form 36 Health Survey (SF-36)
Time frame: 4 weeks
self-efficacy
questionnaire: Allgemeine Selbstwirksamkeit Kurzskala (ASKU)
Time frame: 4 weeks
activities of daily living
questionnaire: Late-Life Function \& Disability Instrument (LLFDI)
Time frame: 4 weeks